

Supplementary Table 1 Clinical and biochemical outcomes

	Steroid-Free Remission 12M				Univariate analysis		Multivariate analysis	
	No		Sí		OR (95% CI)	P value	OR (95% CI)	P value
	N	%	N	%				
Sex								
Female	10	40.0	17	54.8		0.271		
Male	15	60.0	14	45.2		Ref.		
Disease extension								
Extensive colitis	16	64.0	18	54.5		Ref.		
Left-sided colitis	8	32.0	12	36.4		0.615		
Proctitis	1	4.0	3	9.1		0.416		
Perianal involvement	4	16.0	0	0		0.999		
Smoking status								
Former smoker	4	16.0	2	6.5		0.244		
Current smoker	1	4.0	0	0		-		
Non-smoker	20	80.0	29	93.5		Ref.		
Extraintestinal manifestations	7	28.0	6	18.2		0.378		
Prior biologic treatments								
Infliximab	21	84.0	24	72.7		0.313		
Adalimumab	10	40.0	12	36.4		0.778		
Golimumab	2	8.0	6	18.2		0.278		
Vedolizumab	14	56.0	12	36.4		0.139		0.845
Ustekinumab	11	44.0	6	18.2	0.3	(0.1-	0.037	0.156
Tofacitinib	9	36.0	5	15.2	0.9)	0.073		0.795
Concomitant corticosteroid treatment	10	41.7	12	37.5		0.752		
Concomitant immunomodulator treatment	1	4.0	3	9.1		0.461		
Zoster virus vaccination	14	56.0	22	68.8		0.324		
Recent colonoscopy performed	16	64.0	23	69.7		0.647		
	Median	IQR	Median	IQR				
Age	35	24.0-43.5	39	31.3-52.8		0.164		0.803
Years of disease	9	3.5-12.5	13	6-18		0.122		0.349
Number of prior biologic treatments	3	1-4	1	1-3		0.064		0.678
CRP	6	3.4-17.5	6	2.1-19.9		0.441		
Calprotectin	2200	1522.3-2754.3	2000	678-2983		0.228		
AST	16	13-20	17	15-25		0.727		
ALT	16	12-23.5	15	14-28		0.884		
Hemoglobin	12.8	11.2-15.2	13.5	12.6-15.1		0.450		
Leukocytes	8.2	6.9-11.6	8.1	6.6-11.0		0.673		
Neutrophils	4.9	3.0-7.7	4.9	3.6-6.8		0.989		
Platelets	275	232.0-420.5	300	254.5-382.0		0.448		

Cholesterol	164	139.3-190.5	178	158.5- 194.5	0.122	0.088
Triglycerides	87.5	67.5-138.8	80	61-107	0.177	0.205
